340 Kingsland Street
This site is no longer operational. Please visit Roche’s headquarters here.
Roche, founded in 1896, is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
342 articles with Roche
Roche Boosts Presence in China; Plans to Expand Jobs, Diagnostic Operations And Pharmaceutical Research and Development
OncoMethylome Sciences S.A. to Perform MGMT Testing in Roche Phase III Study of Avastin for Glioblastoma
Hoffmann-La Roche Inc. Release: New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Hoffmann-La Roche Inc. Release: CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
Roche: Final Gemini Study Results Confirm Boosted Invirase Was as Effective as Kaletra While Providing an Improved Triglyceride Profile for HIV Patients
Hoffmann-La Roche Inc. Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
Hoffmann-La Roche Inc. New Data Suggest Boosted Invirase(R) has Similar Efficacy to Boosted Lopinavir in HIV Patients at 24 Weeks
Hoffmann-La Roche Inc.: Data Suggest that PEGASYS(R) May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron(R)
Hoffmann-La Roche Inc. Submits Application to the FDA for use of XELOX With or Without Avastin(R) for the Treatment of Advanced Colorectal Cancer